Comparative Pharmacology
Head-to-head clinical analysis: MELPHALAN HYDROCHLORIDE versus ZEPZELCA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELPHALAN HYDROCHLORIDE versus ZEPZELCA.
MELPHALAN HYDROCHLORIDE vs ZEPZELCA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Melphalan is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription. It is cell cycle phase-nonspecific.
Lurbinectedin is a selective inhibitor of oncogenic transcription. It binds to the minor groove of DNA, inhibiting the activity of RNA polymerase II and promoting its degradation, thereby reducing transcription of certain oncogenes and inducing apoptosis in cancer cells.
16 mg/m² intravenously over 15-20 minutes every 2 weeks for 4 doses, then every 4 weeks
3.24 mg/m2 intravenously over 60 minutes every 21 days until disease progression or unacceptable toxicity.
None Documented
None Documented
1.5-2.5 h (terminal) in normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is approximately 7-9 hours in patients with normal hepatic function, supporting once-daily dosing.
Renal: 10-30% unchanged; fecal: 20-30% as metabolites; biliary: minor.
Primarily hepatic metabolism, with biliary/fecal excretion as the major route (approximately 60-80% of the administered dose). Renal excretion accounts for <20% of the dose as unchanged drug and metabolites.
Category D/X
Category C
Alkylating Agent
Alkylating Agent